FDA Grants Priority Review to Novartis's CAR-T Cell Therapy Novartis announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed and refractory (r/r) pediatric and youthful adult patients with B-cell acute lymphoblastic leukemia (ALL).…